Innovate Clinical Strategy
We are expanding our clinical capacity and creating a state-of-the-art patient experience, bringing our world-class care to people everywhere, through MSK’s trailblazing new Pavilion, our regional sites, and even our patients’ own homes. Not only will we improve their health but we also will support their needs. We treat people in the context of their lives.
Nurse Brittney Grannum helps a patient recover by connecting on a personal level. Understanding what matters most to patients is an essential part of cancer care at MSK.
Graduate student Lucia Wang and molecular biologist Dr. Dirk Remus are researching how DNA is copied when cells divide, grow, and repair.
Drive Scientific Discovery
Before scientists could develop immunotherapies, they needed to find out how the immune system interacts with cancer cells. Before researchers could create precision oncology drugs, they needed to understand that many cancers are caused by genetic mutations. Beneath every bold and lifesaving innovation, there are teams of scientists driven to understand the fundamentals of human biology and apply those discoveries to improve and save lives.
Harness the Immune System
Cancer immunotherapy is one of the most transformational breakthroughs in modern medicine, and many of the greatest advances were led by MSK. Our researchers continue striving to understand the immune system in all of its complexity, to boost the body’s innate power to fight cancer — especially solid tumors.
Medical oncologists Dr. Luis Diaz Jr. (Grayer Family Chair) and Dr. Andrea Cercek with patients who joined a practice-changing clinical trial. Immunotherapy achieved 100% remission in patients with a certain type of rectal cancer.
Cancer biologist Dr. Nikolaus Schultz, molecular geneticist Dr. Debyani Chakravarty, and physician scientist Dr. David Solit (Geoffrey Beene Chair) collaborate on powerful new precision therapies and diagnostic tools.
Expand Precision Oncology
MSK helped usher in the era of precision medicine, in which a patient’s cancer treatment is tailored to the molecular characteristics of their disease. We developed MSK-IMPACT®, the first tumor-sequencing test of its kind to be authorized by the Food and Drug Administration. Although we’ve since identified more than 500 genetic mutations linked to various cancers, much work remains to find more drugs to target and stop them from driving cancer growth.
Transform Data Into Cures
Data science offers unprecedented insights into each patient’s cancer and helps guide treatment decisions. Because MSK has gathered a vast amount of information from caring for hundreds of thousands of patients, we are uniquely able to analyze key details that will help us improve cancer diagnosis, predict responses to therapy, and continuously advance patient care. The lessons learned at MSK benefit patients across America and around the world.
Computational oncologist Dr. Sohrab Shah (Nicholls-Biondi Chair) leads a team of skilled data scientists who have chosen to use their specialized knowledge to advance cancer research.
Cell biologist Dr. Philipp Niethammer talks to MSK students. Teaching is deeply engrained in MSK’s culture. Each year, MSK trains more than 2,300 residents, fellows, and PhD candidates.
Develop the New Generation of Leaders
There is an urgent demand for exceptionally skilled physicians, scientists, and other professionals to discover new treatments and to make the best cancer care available to the most patients. We are committed to recruiting, training, and retaining the pioneers of tomorrow.